Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI).
<h4>Background</h4>Atrial fibrillation (AF) adds significant risk of stroke and thromboembolism in patients on hemodialysis (HD). The aim of this study was to investigate the prevalence of AF in a population-based cohort of HD patients and practice patterns of antithrombotic therapy for...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0169400&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849716871770669056 |
|---|---|
| author | Oliver Königsbrügge Florian Posch Marlies Antlanger Josef Kovarik Renate Klauser-Braun Josef Kletzmayr Sabine Schmaldienst Martin Auinger Günther Zuntner Matthias Lorenz Ella Grilz Gerald Stampfel Stefan Steiner Ingrid Pabinger Marcus Säemann Cihan Ay |
| author_facet | Oliver Königsbrügge Florian Posch Marlies Antlanger Josef Kovarik Renate Klauser-Braun Josef Kletzmayr Sabine Schmaldienst Martin Auinger Günther Zuntner Matthias Lorenz Ella Grilz Gerald Stampfel Stefan Steiner Ingrid Pabinger Marcus Säemann Cihan Ay |
| author_sort | Oliver Königsbrügge |
| collection | DOAJ |
| description | <h4>Background</h4>Atrial fibrillation (AF) adds significant risk of stroke and thromboembolism in patients on hemodialysis (HD). The aim of this study was to investigate the prevalence of AF in a population-based cohort of HD patients and practice patterns of antithrombotic therapy for stroke prevention in AF.<h4>Methods</h4>The Vienna InVestigation of AtriaL fibrillation and thromboembolism in patients on hemodialysis (VIVALDI), an ongoing prospective observational cohort study, investigates the prevalence of AF and the risk of thromboembolic events in HD patients in Vienna, Austria. We analyzed cross-sectional data of 626 patients (63.4% men, median age 66 years, approx. 73% of HD patients in Vienna), who provided informed consent. A structured interview with each patient was performed, recent and archived ECGs were viewed and medical histories were verified with electronic records.<h4>Results</h4>The overall prevalence of AF was 26.5% (166 patients, 71.1% men, median age 72 years) of which 57.8% had paroxysmal AF, 3.0% persistent AF, 32.5% permanent AF, and 6.6% of patients had newly diagnosed AF. The median CHA2DS2-VASc Score was 4 [25th-75th percentile 3-5]. In multivariable analysis, AF was independently associated with age (odds ratio: 1.05 per year increase, 95% confidence interval: 1.03-1.07), male sex (1.7, 1.1-2.6), history of venous thromboembolism (2.0, 1.1-3.6), congestive heart failure (1.7, 1.1-2.5), history of or active cancer (1.5, 1.0-2.4) and time on HD (1.08 per year on HD, 1.03-1.13). Antithrombotic treatment was applied in 84.4% of AF patients (anticoagulant agents in 29.5%, antiplatelet agents in 33.7%, and both in 21.1%). In AF patients, vitamin-K-antagonists were used more often than low-molecular-weight heparins (30.1% and 19.9%).<h4>Conclusions</h4>The prevalence of AF is high amongst HD patients and is associated with age, sex, and distinct comorbidities. Practice patterns of antithrombotic treatment indicate a lack of consensus for stroke prevention in HD patients with AF. |
| format | Article |
| id | doaj-art-2eb0db03bbec45d2bc620d4fe06c6920 |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-2eb0db03bbec45d2bc620d4fe06c69202025-08-20T03:12:50ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01121e016940010.1371/journal.pone.0169400Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI).Oliver KönigsbrüggeFlorian PoschMarlies AntlangerJosef KovarikRenate Klauser-BraunJosef KletzmayrSabine SchmaldienstMartin AuingerGünther ZuntnerMatthias LorenzElla GrilzGerald StampfelStefan SteinerIngrid PabingerMarcus SäemannCihan Ay<h4>Background</h4>Atrial fibrillation (AF) adds significant risk of stroke and thromboembolism in patients on hemodialysis (HD). The aim of this study was to investigate the prevalence of AF in a population-based cohort of HD patients and practice patterns of antithrombotic therapy for stroke prevention in AF.<h4>Methods</h4>The Vienna InVestigation of AtriaL fibrillation and thromboembolism in patients on hemodialysis (VIVALDI), an ongoing prospective observational cohort study, investigates the prevalence of AF and the risk of thromboembolic events in HD patients in Vienna, Austria. We analyzed cross-sectional data of 626 patients (63.4% men, median age 66 years, approx. 73% of HD patients in Vienna), who provided informed consent. A structured interview with each patient was performed, recent and archived ECGs were viewed and medical histories were verified with electronic records.<h4>Results</h4>The overall prevalence of AF was 26.5% (166 patients, 71.1% men, median age 72 years) of which 57.8% had paroxysmal AF, 3.0% persistent AF, 32.5% permanent AF, and 6.6% of patients had newly diagnosed AF. The median CHA2DS2-VASc Score was 4 [25th-75th percentile 3-5]. In multivariable analysis, AF was independently associated with age (odds ratio: 1.05 per year increase, 95% confidence interval: 1.03-1.07), male sex (1.7, 1.1-2.6), history of venous thromboembolism (2.0, 1.1-3.6), congestive heart failure (1.7, 1.1-2.5), history of or active cancer (1.5, 1.0-2.4) and time on HD (1.08 per year on HD, 1.03-1.13). Antithrombotic treatment was applied in 84.4% of AF patients (anticoagulant agents in 29.5%, antiplatelet agents in 33.7%, and both in 21.1%). In AF patients, vitamin-K-antagonists were used more often than low-molecular-weight heparins (30.1% and 19.9%).<h4>Conclusions</h4>The prevalence of AF is high amongst HD patients and is associated with age, sex, and distinct comorbidities. Practice patterns of antithrombotic treatment indicate a lack of consensus for stroke prevention in HD patients with AF.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0169400&type=printable |
| spellingShingle | Oliver Königsbrügge Florian Posch Marlies Antlanger Josef Kovarik Renate Klauser-Braun Josef Kletzmayr Sabine Schmaldienst Martin Auinger Günther Zuntner Matthias Lorenz Ella Grilz Gerald Stampfel Stefan Steiner Ingrid Pabinger Marcus Säemann Cihan Ay Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI). PLoS ONE |
| title | Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI). |
| title_full | Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI). |
| title_fullStr | Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI). |
| title_full_unstemmed | Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI). |
| title_short | Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI). |
| title_sort | prevalence of atrial fibrillation and antithrombotic therapy in hemodialysis patients cross sectional results of the vienna investigation of atrial fibrillation and thromboembolism in patients on hemodialysis vivaldi |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0169400&type=printable |
| work_keys_str_mv | AT oliverkonigsbrugge prevalenceofatrialfibrillationandantithrombotictherapyinhemodialysispatientscrosssectionalresultsoftheviennainvestigationofatrialfibrillationandthromboembolisminpatientsonhemodialysisvivaldi AT florianposch prevalenceofatrialfibrillationandantithrombotictherapyinhemodialysispatientscrosssectionalresultsoftheviennainvestigationofatrialfibrillationandthromboembolisminpatientsonhemodialysisvivaldi AT marliesantlanger prevalenceofatrialfibrillationandantithrombotictherapyinhemodialysispatientscrosssectionalresultsoftheviennainvestigationofatrialfibrillationandthromboembolisminpatientsonhemodialysisvivaldi AT josefkovarik prevalenceofatrialfibrillationandantithrombotictherapyinhemodialysispatientscrosssectionalresultsoftheviennainvestigationofatrialfibrillationandthromboembolisminpatientsonhemodialysisvivaldi AT renateklauserbraun prevalenceofatrialfibrillationandantithrombotictherapyinhemodialysispatientscrosssectionalresultsoftheviennainvestigationofatrialfibrillationandthromboembolisminpatientsonhemodialysisvivaldi AT josefkletzmayr prevalenceofatrialfibrillationandantithrombotictherapyinhemodialysispatientscrosssectionalresultsoftheviennainvestigationofatrialfibrillationandthromboembolisminpatientsonhemodialysisvivaldi AT sabineschmaldienst prevalenceofatrialfibrillationandantithrombotictherapyinhemodialysispatientscrosssectionalresultsoftheviennainvestigationofatrialfibrillationandthromboembolisminpatientsonhemodialysisvivaldi AT martinauinger prevalenceofatrialfibrillationandantithrombotictherapyinhemodialysispatientscrosssectionalresultsoftheviennainvestigationofatrialfibrillationandthromboembolisminpatientsonhemodialysisvivaldi AT guntherzuntner prevalenceofatrialfibrillationandantithrombotictherapyinhemodialysispatientscrosssectionalresultsoftheviennainvestigationofatrialfibrillationandthromboembolisminpatientsonhemodialysisvivaldi AT matthiaslorenz prevalenceofatrialfibrillationandantithrombotictherapyinhemodialysispatientscrosssectionalresultsoftheviennainvestigationofatrialfibrillationandthromboembolisminpatientsonhemodialysisvivaldi AT ellagrilz prevalenceofatrialfibrillationandantithrombotictherapyinhemodialysispatientscrosssectionalresultsoftheviennainvestigationofatrialfibrillationandthromboembolisminpatientsonhemodialysisvivaldi AT geraldstampfel prevalenceofatrialfibrillationandantithrombotictherapyinhemodialysispatientscrosssectionalresultsoftheviennainvestigationofatrialfibrillationandthromboembolisminpatientsonhemodialysisvivaldi AT stefansteiner prevalenceofatrialfibrillationandantithrombotictherapyinhemodialysispatientscrosssectionalresultsoftheviennainvestigationofatrialfibrillationandthromboembolisminpatientsonhemodialysisvivaldi AT ingridpabinger prevalenceofatrialfibrillationandantithrombotictherapyinhemodialysispatientscrosssectionalresultsoftheviennainvestigationofatrialfibrillationandthromboembolisminpatientsonhemodialysisvivaldi AT marcussaemann prevalenceofatrialfibrillationandantithrombotictherapyinhemodialysispatientscrosssectionalresultsoftheviennainvestigationofatrialfibrillationandthromboembolisminpatientsonhemodialysisvivaldi AT cihanay prevalenceofatrialfibrillationandantithrombotictherapyinhemodialysispatientscrosssectionalresultsoftheviennainvestigationofatrialfibrillationandthromboembolisminpatientsonhemodialysisvivaldi |